US 12,403,155 B2
Methods and compositions for the activation of gamma-delta T-cells
Charles David Pauza, Rockville, MD (US); Haishan Li, Rockville, MD (US); Tyler Lahusen, Rockville, MD (US); and Mei-Ling Liou, Rockville, MD (US)
Assigned to American Gene Technologies International Inc., Rockville, MD (US)
Filed by American Gene Technologies International Inc., Rockville, MD (US)
Filed on Nov. 15, 2022, as Appl. No. 18/055,525.
Application 18/055,525 is a continuation of application No. 16/988,427, filed on Aug. 7, 2020, granted, now 11,534,450.
Application 16/988,427 is a continuation of application No. 16/530,908, filed on Aug. 2, 2019, granted, now 10,772,905, issued on Sep. 15, 2020.
Application 16/530,908 is a continuation of application No. 16/132,247, filed on Sep. 14, 2018, granted, now 10,420,789, issued on Sep. 14, 2019.
Application 16/132,247 is a continuation of application No. 15/904,131, filed on Feb. 23, 2018, granted, now 10,137,144, issued on Nov. 27, 2018.
Application 15/904,131 is a continuation in part of application No. 15/652,080, filed on Jul. 17, 2017, granted, now 9,914,938, issued on Mar. 13, 2018.
Application 15/652,080 is a continuation of application No. PCT/US2017/013399, filed on Jan. 13, 2017.
Claims priority of provisional application 62/279,474, filed on Jan. 15, 2016.
Prior Publication US 2023/0277579 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/675 (2006.01); A61K 31/7105 (2006.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); A61P 35/02 (2006.01); C12N 15/86 (2006.01); C12Q 1/68 (2018.01)
CPC A61K 31/7105 (2013.01) [A61K 31/675 (2013.01); A61K 47/6807 (2017.08); A61K 47/6901 (2017.08); A61P 35/02 (2018.01); C12N 15/1137 (2013.01); C12N 15/86 (2013.01); C12Y 205/0101 (2013.01); A61K 2300/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2330/51 (2013.01); C12N 2740/16032 (2013.01); C12N 2740/16043 (2013.01); C12N 2740/16045 (2013.01); C12N 2750/14143 (2013.01); C12N 2810/6072 (2013.01)] 16 Claims
 
1. A pharmaceutical combination, comprising:
(a) a bisphosphonate drug; and
(b) a lentiviral particle comprising an envelope protein and a therapeutic vector comprising:
an EF-1 alpha promoter and
at least one encoded shRNA or microRNA that, when expressed, inhibits production of farnesyl diphosphate synthase (FDPS)
wherein the bisphosphonate drug and lentiviral particle are administered together or separately,
wherein the at least one encoded shRNA or microRNA comprises a sequence having at least 80 percent identity with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.